BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19265481)

  • 1. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.
    Madhi SA; Klugman KP; Kuwanda L; Cutland C; Käyhty H; Adrian P
    J Infect Dis; 2009 Apr; 199(8):1168-76. PubMed ID: 19265481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Song LY; Fenton T; Nachman SA; Levin MJ; Rosenblatt HM; Pelton SI; Borkowsky W; Edwards KM; Peters J;
    Pediatrics; 2007 Nov; 120(5):e1190-202. PubMed ID: 17938165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.
    Spoulou VI; Tsoumas DL; Papaevangelou VG; Mostrou GI; Theodoridou MC
    Vaccine; 2005 Nov; 23(46-47):5289-93. PubMed ID: 16054732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
    Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
    Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
    Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
    Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Vaccine; 2004 Jul; 22(21-22):2696-700. PubMed ID: 15246599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
    French N; Moore M; Haikala R; Kayhty H; Gilks CF
    J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children.
    Ditse Z; Adrian PV; Kuwanda L; Madhi SA
    Vaccine; 2013 Sep; 31(40):4421-7. PubMed ID: 23845819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.